JP2008521788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521788A5 JP2008521788A5 JP2007542134A JP2007542134A JP2008521788A5 JP 2008521788 A5 JP2008521788 A5 JP 2008521788A5 JP 2007542134 A JP2007542134 A JP 2007542134A JP 2007542134 A JP2007542134 A JP 2007542134A JP 2008521788 A5 JP2008521788 A5 JP 2008521788A5
- Authority
- JP
- Japan
- Prior art keywords
- dispersant
- active ingredient
- pharmaceutically active
- particles
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002270 dispersing agent Substances 0.000 claims 45
- 239000004480 active ingredient Substances 0.000 claims 39
- 239000002245 particle Substances 0.000 claims 32
- 238000000034 method Methods 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 15
- 238000009472 formulation Methods 0.000 claims 10
- 239000003380 propellant Substances 0.000 claims 8
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 7
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 7
- 239000011246 composite particle Substances 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 239000006184 cosolvent Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Chemical class 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 210000002934 adrenergic neuron Anatomy 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 150000003862 amino acid derivatives Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127090 anticoagulant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 239000003668 hormone analog Substances 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 150000003873 salicylate salts Chemical class 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- -1 sulfonylureas Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 229940064707 sympathomimetics Drugs 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0426301.8 | 2004-11-30 | ||
| GBGB0426301.8A GB0426301D0 (en) | 2004-11-30 | 2004-11-30 | Pharmaceutical formulations |
| PCT/GB2005/050220 WO2006059152A2 (en) | 2004-11-30 | 2005-11-30 | Pharmaceutical formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008521788A JP2008521788A (ja) | 2008-06-26 |
| JP2008521788A5 true JP2008521788A5 (https=) | 2009-01-29 |
| JP5317319B2 JP5317319B2 (ja) | 2013-10-16 |
Family
ID=33561610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007542134A Expired - Fee Related JP5317319B2 (ja) | 2004-11-30 | 2005-11-30 | 医薬製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080220078A1 (https=) |
| EP (1) | EP1817015A2 (https=) |
| JP (1) | JP5317319B2 (https=) |
| CN (1) | CN101083979A (https=) |
| CA (1) | CA2589453C (https=) |
| GB (1) | GB0426301D0 (https=) |
| WO (1) | WO2006059152A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2283818B1 (en) | 2000-11-30 | 2017-08-02 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| EP3788877B1 (en) * | 2007-04-11 | 2024-08-07 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| GB0712316D0 (en) * | 2007-06-26 | 2007-08-01 | Entripneur Ltd | A novel powder and its method of manufacture |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US20130160761A1 (en) * | 2008-11-04 | 2013-06-27 | Cipla Limited | Pharmaceutical Aerosol Composition |
| EP2382351B1 (en) | 2009-01-29 | 2012-10-31 | Director General, Defence Research & Development Organisation | A wool care composition |
| MX337126B (es) * | 2009-05-29 | 2016-02-12 | Pearl Therapeutics Inc | Administracion respiratoria de agentes activos. |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| GB0910375D0 (en) | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| DE102009049470A1 (de) * | 2009-10-15 | 2011-04-28 | Süd-Chemie AG | Verfahren zur Herstellung von feinteiligen Lithiumtitan-Spinellen und deren Verwendung |
| US20110229418A1 (en) * | 2010-03-18 | 2011-09-22 | Steven Lehrer | Compositions and Methods of Treating and Preventing Lung Cancer |
| US9248110B2 (en) | 2010-03-18 | 2016-02-02 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis |
| BR112012024059B1 (pt) * | 2010-04-01 | 2021-06-01 | Chiesi Farmaceutici S.P.A. | Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco |
| CN102309456B (zh) * | 2010-07-02 | 2013-05-01 | 北京化工大学 | 一种厄贝沙坦纳微复合粉体与片剂及其制备方法 |
| CN102836125A (zh) * | 2011-06-23 | 2012-12-26 | 王晓青 | 治疗低血容量休克的丙戊酸及其盐的鼻腔给药制剂 |
| RU2629085C2 (ru) | 2011-10-11 | 2017-08-24 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Кристаллические микрочастицы бета-агониста, покрытые жирной кислотой |
| KR102391332B1 (ko) | 2013-03-15 | 2022-04-26 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
| US10646452B2 (en) | 2013-03-15 | 2020-05-12 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
| CN104274426A (zh) * | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途 |
| HUE063028T2 (hu) * | 2015-12-24 | 2023-12-28 | Philip Morris Products Sa | Ízesített nikotinpor |
| CN107550919A (zh) * | 2017-09-04 | 2018-01-09 | 杭州旦承医药科技有限公司 | 唑来膦酸的用途及粉雾剂和制备方法 |
| CN107441101A (zh) * | 2017-09-04 | 2017-12-08 | 杭州旦承医药科技有限公司 | 伊班膦酸钠的用途及粉雾剂和制备方法 |
| KR102681843B1 (ko) * | 2017-09-22 | 2024-07-05 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| US10786456B2 (en) * | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2077229B (en) * | 1980-05-16 | 1983-08-03 | Neotechnic Eng Ltd | Valve assembly for a pressurized aerosoldispensing container |
| US4819834A (en) * | 1986-09-09 | 1989-04-11 | Minnesota Mining And Manufacturing Company | Apparatus and methods for delivering a predetermined amount of a pressurized fluid |
| GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
| GB0008411D0 (en) * | 2000-04-05 | 2000-05-24 | Vectura Ltd | Pharmaceutical preparations and their manufacture |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| GB0010709D0 (en) * | 2000-05-03 | 2000-06-28 | Vectura Ltd | Powders for use a in dry powder inhaler |
| PT1296651E (pt) * | 2000-06-27 | 2008-02-12 | Vectura Ltd | Método para fazer partículas para serem usadas numa composição farmacêutica |
| NZ526059A (en) * | 2000-11-30 | 2005-05-27 | Vectura Ltd | Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition |
| EP2168571B1 (en) * | 2000-11-30 | 2018-08-22 | Vectura Limited | Particles for use in a Pharmaceutical Composition |
| EP2283818B1 (en) * | 2000-11-30 | 2017-08-02 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| WO2002043693A2 (en) * | 2000-11-30 | 2002-06-06 | Vectura Limited | Pharmaceutical compositions for inhalation |
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| GB0109384D0 (en) * | 2001-04-12 | 2001-05-30 | Vectura Ltd | Pharmaceutical products, preparation and uses thereof |
| US20050013862A1 (en) * | 2001-09-05 | 2005-01-20 | Vectura Limited | Functional powders for oral delivery |
| WO2003074029A1 (en) * | 2002-03-07 | 2003-09-12 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
| AU2003269284A1 (en) * | 2002-10-11 | 2004-05-04 | Pharmakodex Limited | Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof |
| JP2006522634A (ja) * | 2003-04-14 | 2006-10-05 | ベクトゥラ・リミテッド | 投与効率を向上させるデバイス及び製薬組成 |
| US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
| RU2364400C2 (ru) * | 2003-04-14 | 2009-08-20 | Вектура Лтд | Фармацевтические композиции |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| EP1663164A2 (en) * | 2003-09-15 | 2006-06-07 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
-
2004
- 2004-11-30 GB GBGB0426301.8A patent/GB0426301D0/en not_active Ceased
-
2005
- 2005-11-30 CA CA2589453A patent/CA2589453C/en not_active Expired - Fee Related
- 2005-11-30 US US11/791,670 patent/US20080220078A1/en not_active Abandoned
- 2005-11-30 JP JP2007542134A patent/JP5317319B2/ja not_active Expired - Fee Related
- 2005-11-30 CN CNA2005800410147A patent/CN101083979A/zh active Pending
- 2005-11-30 WO PCT/GB2005/050220 patent/WO2006059152A2/en not_active Ceased
- 2005-11-30 EP EP05813625A patent/EP1817015A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521788A5 (https=) | ||
| AU754379B2 (en) | Therapies for treating pulmonary diseases | |
| WO2004026262A3 (en) | Abuse-resistant pharmaceutical compositions | |
| US5219572A (en) | Controlled release delivery device for macromolecular proteins | |
| US20080317863A1 (en) | Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs | |
| EP0973507B1 (en) | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same | |
| WO2006059152A3 (en) | Pharmaceutical formulations | |
| DE69001898T2 (de) | Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen. | |
| CN105246458A (zh) | 用于治疗剂递送的微阵列及其使用方法 | |
| EP0222411B1 (en) | Method of preparing sustained-release pharmaceutical preparation | |
| JP2004515455A5 (https=) | ||
| CA2391923A1 (en) | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | |
| HUE031229T2 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| EP1356808A3 (en) | Coating technique for deposition of drug substance on a substrate | |
| US20100112054A1 (en) | Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates | |
| WO2007103557A3 (en) | Coating capsules with active pharmaceutical ingredients | |
| JP2018504454A (ja) | 積層徐放型マイクロビーズ及びその作製方法 | |
| CN107252420A (zh) | 罗苏伐他汀钙的药物组合物 | |
| WO2005053638A3 (en) | Composition and delivery system | |
| CZ20033435A3 (cs) | Přípravek obsahující inhibitor PDE@ a antagonistu H�@receptoru a jeho použití pro výrobu léčiva pro léčbu respiračních onemocnění | |
| Demiri et al. | Gluing Pills Technology: A novel route to multilayer tablet manufacturing | |
| US5328697A (en) | Compositions and processes for the sustained release of drugs | |
| NZ504566A (en) | The amorphous form of zafirulkast (Form A), a leukotriene antagonist, as a pharmaceutical composition in a multi-layered sustained release formulation for treatment of asthma and related conditions | |
| WO2007015270A3 (en) | Novel controlled release compositions of selective serotonin reuptake inhibitors | |
| CA2543640A1 (en) | Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action |